Montpellier (France), March 19, 2018 - 5:45 pm CET

Intrasense and 12 Sigma Technologies sign a strategic partnership agreement

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, and 12 Sigma Technologies, a pioneer company to introduce artificial intelligence and deep learning to modern medical diagnosis and data analysis, announce after HIMSS exhibition in Las Vegas a multi-year partnership contract, for the creation of an innovative product based on Myrian® technologies.

A long-term collaboration serving a unique solution for lung cancer

Using Myrian® Studio and based on Myrian® platform, 12 Sigma Technologies has been developing "σ-Discover Lung", a Computer Aided Diagnostics (CAD) system which is based on Deep Learning technology, dedicated to support physicians to analyze and diagnose lung nodules.

Artificial Intelligence technology inspired, σ-Discover Lung is first of its kind on the market. This solution provides accurate detection and segmentation results to help doctors to interpret challenging medical cases. For example, detecting precisely tiny lesions of a medical image, generating a structured report automatically and achieving exceptional accuracy.

Commercial perspectives in China, USA and Europe

Since February 2017, Intrasense supports 12 Sigma Technologies for the development of σ-Discover Lung, based on Myrian® platform and services, enabling a very fast go-to-market strategy.

The commercialization of σ-Discover Lung is first starting in China, the second largest world healthcare market with unprecedented growth, with first commercial contracts in progress. Based in Beijing, Suzhou (China) and San Diego (USA), 12 Sigma will then pursue business development in the USA and Europe. The partnership comprises contractual agreement for Myrian® distribution with of σ-Discover deployment, with very promising market potential and strong financial revenues.

« We are very proud of this strong partnership with a high-tech innovative player such as 12 Sigma Technologies. We are very happy that Myrian® Studio perfectly fits 12 Sigma needs, offering a tailor-made and optimized time-to-market solution. » comments Nicolas Reymond, Chief Executive Officer of Intrasense.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

For more information, please visit www.intrasense.fr.

About 12 Sigma Technologies

12 Sigma Technologies was founded by two entrepreneurs with extensive deep learning and computer vision background in April 2015 in San Diego, California. It's one of the first companies to introduce artificial intelligence and deep learning into modern medical image diagnosis and medical data analysis. Headquartered in Beijing, they also have R&D teams in Suzhou (China) and San Diego, and signed collaboration agreements with more than 50 top-tier hospitals in China and US. The first deep learning product on lung cancer screening "σ—Discover Lung" has entered about 100 hospitals in China and the high sensitivity for identifying lesions get widely recognized of doctor's. The next strategic plan is to let more AI diagnosis systems come into clinical and become an indispensable AI assistant of doctors, the product line will then cover different organs and systems, including the detection and lesions identification all over the body, such as liver, breast, brain, neuro, etc. 12 Sigma works closely with partners in applied medical diagnostics, technical research and clinical trials.

For more information, please visit www.12sigma.cn.

Contacts

Intrasense	12 Sigma Technologies	NewCap
Nicolas Reymond	Xin Zhong	Investor Relations and
Chief Executive Officer	Chief Executive Officer	Financial Communication
1231 avenue du Mondial	11975 El Camino Real,	Valentine Brouchot
98, 34000 Montpellier,	Suite 102, San Diego,	Pierre Laurent
FRANCE	CA, 92130, USA	
Tel: +334 67 130 130	Tel: +1 858 692 2356	Tel: +331 44 71 94 96
investor@intrasense.fr	contact@12sigma.ai	intrasense@newcap.eu

ALINS
EURONEXT
GROWTH